Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Naim U. Rashid

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7274-8259; OpenAlex author ID A5065665275, A5073378127; NIH RePORTER profile ID 8764947. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
66
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper, 1 grant

Papers 14

  1. Limitations of GATA6 and CK5 as surrogate markers for molecular subtyping in pancreatic cancer. Co-author DOI 10.1016/j.hpb.2026.08.001↗
  2. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Co-author DOI 10.1126/scisignal.adu7145↗
  3. Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. Co-author DOI 10.1158/2159-8290.cd-23-1480↗
  4. Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Cla… Co-author DOI 10.1016/j.jmoldx.2024.07.002↗
  5. Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006416↗
  6. Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. Co-author DOI 10.7717/peerj.17797↗
  7. Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model. Co-author DOI 10.1038/s42003-023-04461-6↗
  8. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Co-author DOI 10.1016/j.jbc.2021.101335↗
  9. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1467↗
  10. B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0349↗
  11. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. Co-author DOI 10.1172/jci.insight.129905↗
  12. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.17.00121↗
  13. Radiation therapy for unresectable pancreatic adenocarcinoma: population-based trends in utilization and survival rates in the United States. First author DOI 10.1001/jamasurg.2014.1837↗
  14. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3398↗

Grants 1

  1. Integrating tumor and stroma to understand and predict treatment response U01CA274298↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jen Jen Yeh · 11 shared papers, 1 shared grant, 2015–2026 · strength 2.66
  2. Susan Tsai · 1 shared grant, 2026 · strength 1.00
  3. Gary L. Johnson · 3 shared papers, 2020–2025 · strength 0.49
  4. Alina Cornelia Iuga · 2 shared papers, 2025–2026 · strength 0.48
  5. Jaewon James Lee · 2 shared papers, 2024–2026 · strength 0.47
  6. Richard A. Moffitt · 4 shared papers, 2015–2023 · strength 0.41
  7. Shawn M. Gomez · 2 shared papers, 2024–2025 · strength 0.39
  8. Lee M. Graves · 3 shared papers, 2020–2025 · strength 0.38
  9. Matthew B. Lipner · 2 shared papers, 2020–2024 · strength 0.30
  10. Saryn Doucette · 1 shared paper, 2026 · strength 0.29
  11. Mohammed Aldakkak · 1 shared paper, 2026 · strength 0.29
  12. Douglas B. Evans · 1 shared paper, 2026 · strength 0.29
  13. J. Nathaniel Diehl · 2 shared papers, 2021–2025 · strength 0.29
  14. Priya S. Hibshman · 2 shared papers, 2021–2025 · strength 0.29
  15. Mariaelena Pierobon · 2 shared papers, 2021–2025 · strength 0.29
  16. Adrienne D. Cox · 2 shared papers, 2021–2025 · strength 0.29
  17. Jennifer E. Klomp · 2 shared papers, 2021–2025 · strength 0.29
  18. Channing J. Der · 2 shared papers, 2021–2025 · strength 0.29
  19. Ryan R. Kawalerski · 2 shared papers, 2020–2023 · strength 0.27
  20. Yan Li · 1 shared paper, 2024 · strength 0.22
  21. Margaret L. Gulley · 1 shared paper, 2024 · strength 0.22
  22. Matthew E. Berginski · 1 shared paper, 2024 · strength 0.20
  23. Michael Haas · 1 shared paper, 2025 · strength 0.19
  24. Steffen Ormanns · 1 shared paper, 2025 · strength 0.19
  25. Lisa Miller‐Phillips · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.